CoChat

Adverse effects from antidepressant treatment: randomised controlled trial of 601 depressed individuals

Open access
Crawford, Andrew A., Lewis, Sarah, Nutt, David, Peters, Tim J., Cowen, Philip, O’Donovan, Michael C., Wiles, Nicola, Lewis, Glyn · 2014 · Psychopharmacology
Cited by 69

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

RATIONALE: Premature discontinuation of antidepressant drugs is a frequent clinical problem. Adverse effects are common, occur early on in treatment and are reported to be one of the main reasons for discontinuation of antidepressant treatment. OBJECTIVES: To investigate the association between adverse effects occurring in the first 2 weeks of antidepressant treatment and discontinuation by 6 weeks as the outcome. To investigate the time profile of adverse effects induced by the selective serotonin reuptake inhibitor citalopram and the noradrenaline reuptake inhibitor reboxetine over 12 weeks of treatment. METHODS: Six hundred and one depressed individuals were randomly allocated to either citalopram (20 mg daily) or reboxetine (4 mg twice daily). A modified version of the Toronto Side Effects Scale was used to measure 14 physical symptoms at baseline (medication free) and at 2, 6 and 12 weeks after randomisation. RESULTS: Individuals randomised to reboxetine reported a greater number of adverse effects and were more likely to stop treatment than individuals receiving citalopram. Dizziness (OR 1.83; 95% CI 1.09, 3.09; p = 0.02) and the total number of adverse effects (OR 1.12; 95% CI 1.00, 1.25; p = 0.06) reported at 2 weeks were associated with discontinuation from overall antidepressant treatment by 6 weeks. Reports of adverse effects tended to reduce throughout the 12 weeks for both antidepressants. CONCLUSIONS: The majority of adverse effects were not individually associated with discontinuation from antidepressant treatment. Reports of physical symptoms tended to reduce over time. The physical symptoms that did not reduce over time may represent symptoms of depression rather than antidepressant-induced adverse effects.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00213-014-3467-8

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Research works printed but not linked: 40

  1. Anderson IM, Ferrier IN, Baldwin RC, Cowen PJ, Howard L, Lewis G, Matthews K, McAllister-Williams RH, Peveler RC, Scott J, Tylee A, P. British Assoc (2008) Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol 22:343–396 · DOI · Paper page
  2. Andersson KE (2011) Mechanisms of penile erection and basis for pharmacological treatment of erectile dysfunction. Pharmacol Rev 63:811–859 · DOI · Paper page
  3. Bailey JE, Potokar J, Coupland N, Nutt DJ (1995) The 5-HT3 antagonist ondansetron reduces gastrointestinal side-effects induced by a specific serotonin reuptake inhibitor in man. J Psychopharmacol 9:137–141 · DOI · Paper page
  4. Beck AT, Erbaugh J, Ward CH, Mock J, Mendelsohn M (1961) An inventory for measuring depression. Arch Gen Psychiatry 4:561–571 · DOI · Paper page
  5. Bull SA, Hunkeler EM, Lee JY, Rowland CR, Williamson TE, Schwab JR, Hurt SW (2002) Discontinuing or switching selective serotonin-reuptake inhibitors. Ann Pharmacother 36:578–584 · doi:10.1345/aph.1a254 · Paper page
  6. Clayton AH, Zajecka J, Ferguson JM, Filipiak-Reisner JK, Brown MT, Schwartz GE (2003) Lack of sexual dysfunction with the selective noradrenaline reuptake inhibitor reboxetine during treatment for major depressive disorder. Int Clin Psychopharmacol 18:151–156
  7. Cramer JA, Rosenheck R (1998) Compliance with medication regimens for mental and physical disorders. Psychiatr Serv 49:196–201 · DOI · Paper page
  8. Demyttenaere K, Enzlin P, Dewe W, Boulanger B, De Bie J, De Troyer W, Mesters P (2001) Compliance with antidepressants in a primary care setting, 1: beyond lack of efficacy and adverse events. J Clin Psychiatry 62:30–33 · DOI · Paper page
  9. Donoghue J, Tylee A, Wildgust H (1996) Cross sectional database analysis of antidepressant prescribing in general practice in the United Kingdom, 1993–5. Br Med J 313:861–862 · DOI · Paper page
  10. Dunn RL, Donoghue JM, Ozminkowski RJ, Stephenson D, Hylan TR (1999) Longitudinal patterns of antidepressant prescribing in primary care in the UK: comparison with treatment guidelines. J Psychopharmacol 13:136–143 · DOI · Paper page
  11. Eyding D, Lelgemann M, Grouven U, Haerter M, Kromp M, Kaiser T, Kerekes MF, Gerken M, Wieseler B (2010) Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials. BMJ 341:c4737 · DOI · Paper page
  12. Ferguson JM (2001b) The effects of antidepressants on sexual functioning in depressed patients: a review. J Clin Psychiatry 62:22–34 · DOI · Paper page
  13. Frank E, Judge R (2001) Treatment recommendations versus treatment realities: recognizing the rift and understanding the consequences. J Clin Psychiatry 62:10–15 · DOI
  14. Greist J, McNamara RK, Mallinckrodt CH, Rayamajhi JN, Raskin J (2004) Incidence and duration of antidepressant-induced nausea: duloxetine compared with paroxetine and fluoxetine. Clin Ther 26:1446–1455 · DOI
  15. Gruenberg AM (2009) Stahl's essential psychopharmacology: neuroscientific basis and practical applications, third edition. Psychol Med 39:520–521 · doi:10.1017/s0033291708005060
  16. Hajos M, Fleishaker JC, Filipiak-Reisner JK, Brown MT, Wong EHF (2004) The selective norepinephrine reuptake inhibitor antidepressant reboxetine: pharmacological and clinical profile. CNS Drug Rev 10:23–44 · DOI · Paper page
  17. Haug TT, Mykletun A, Dahl AA (2004) The association between anxiety, depression, and somatic symptoms in a large population: the HUNT-II study. Psychosom Med 66:845–851 · DOI · Paper page
  18. Krska J, Morecroft CW (2013) Patients' use of information about medicine side effects in relation to experiences of suspected adverse drug reactions: a cross-sectional survey in medical in-patients. Drug Saf 36:673–680 · doi:10.1007/s40264-013-0065-3
  19. Lamb GC, Green SS, Heron J (1994) Can physicians warn patients of potential side-effects without fear of causing those side effects. Arch Intern Med 154:2753–2756 · DOI
  20. Langworth S, Bodlund O, Agren H (2006) Efficacy and tolerability of reboxetine compared with citalopram—a double-blind study in patients with major depressive disorder. J Clin Psychopharmacol 26:121–127 · DOI · Paper page
  21. Lewis G (1994) Assessing psychiatric-disorder with a human interviewer or a computer. J Epidemiol Community Health 48:207–210 · DOI · Paper page
  22. Lewis G, Mulligan J, Wiles N, Cowen P, Craddock N, Ikeda M, Grozeva D, Mason V, Nutt D, Sharp D (2011) Polymorphism of the 5-HT transporter and response to antidepressants: randomised controlled trial. Br J Psychiatry 198:464 · DOI · Paper page
  23. Lingam R, Scott J (2002) Treatment non-adherence in affective disorders. Acta Psychiatr Scand 105:164–172 · DOI · Paper page
  24. Masand PS (2003) Tolerability and adherence issues in antidepressant therapy. Clin Ther 25:2289–2304 · DOI · Paper page
  25. Middleton HC, Nutt DJ, Anastassiades P (1988) Evidence that imipramine-induced postural hypotension may be centrally mediated. Hum Psychopharmacol Clin Exp 3:181–190 · doi:10.1002/hup.470030305
  26. Moeller HJ (2001) Methodological aspects in the assessment of severity of depression by the Hamilton Depression Scale. Eur Arch Psychiatry Clin Neurosci 251:13–20 · DOI
  27. Montgomery SA, Bebbington P, Cowen P, Deakin W, Freeling P, Hallstrom C, Katona C, King D, Leonard B (1993) Guidelines for treating depressive illness with antidepressants: a statement from the British Association for Psychopharmacology. J Psychopharmacol 7:19–23 · DOI
  28. Morehouse R, MacQueen G, Kennedy SH (2011) Barriers to achieving treatment goals: a focus on sleep disturbance and sexual dysfunction. J Affect Disord 132:S14–S20 · DOI
  29. NHS (2011) Prescription Cost Analysis England 2010. P. U. NHS Information Centre for Health and Social Care, London
  30. Nutt DJ, Glue P (1991) Imipramine in panic disorder. 2. Effects on alpha2-adrenoceptor function. Journal of psychopharmacol (Oxford, England) 5:135–141 · DOI
  31. Schweitzer I, Maguire K, Ng C (2009) Sexual side-effects of contemporary antidepressants: review. Aust N Z J Psychiatry 43:795–808 · DOI · Paper page
  32. StataCorp (2011) Stata statistical software. College station. StataCorp LP, TX
  33. Thomas L, Mulligan J, Mason V, Tallon D, Wiles N, Cowen P, Nutt D, O'Donovan M, Sharp D, Peters T, Lewis G (2008) GENetic and clinical predictors of treatment response in depression: the GenPod randomised trial protocol. Trials 9:29 · DOI
  34. Thompson AJ (2013) Recent developments in 5-HT3 receptor pharmacology. Trends Pharmacol Sci 34:100–109 · DOI
  35. Uher R, Farmer A, Henigsberg N, Rietschel M, Mors O, Maier W, Kozel D, Hauser J, Souery D, Placentino A, Strohmaier J, Perroud N, Zobel A, Rajewska-Rager A, Dernovsek MZ, Larsen ER, Kalember P, Giovannini C, Barreto M, McGuffin P, Aitchison KJ (2009a) Adverse reactions to antidepressants. Br J Psychiatry 195:202–210 · DOI · Paper page
  36. Uher R, Maier W, Hauser J, Marusic A, Schmael C, Mors O, Henigsberg N, Souery D, Placentino A, Rietschel M, Zobel A, Dmitrzak-Weglarz M, Petrovic A, Jorgensen L, Kalember P, Giovannini C, Barreto M, Elkin A, Landau S, Farmer A, Aitchison KJ, McGuffin P (2009b) Differential efficacy of escitalopram and nortriptyline on dimensional measures of depression. Br J Psychiatry 194:252–259 · DOI · Paper page
  37. Vanderkooy J, Kennedy SH, Bagby RM (2002) Antidepressant side effects in depression patients treated in a naturalistic setting: a study of bupropion, moclobemide, paroxetine, sertraline, and venlafaxine. Can J Psychiatry 47:174–180 · DOI · Paper page
  38. Ward E, King M, Lloyd M, Bower P, Sibbald B, Farrelly S, Gabbay M, Tarrier N, Addington-Hall J (2000) Randomised controlled trial of non-directive counselling, cognitive-behaviour therapy, and usual general practitioner care for patients with depression. I: clinical effectiveness. Br Med J 321:1383–1388 · DOI · Paper page
  39. Warden D, Trivedi MH, Wisniewski SR, Kurian B, Zisook S, Kornstein SG, Friedman ES, Miyahara S, Leuchter AF, Fava M, Rush AJ (2010) Early adverse events and attrition in selective serotonin reuptake inhibitor treatment a suicide assessment methodology study report. J Clin Psychopharmacol 30:259–266 · DOI
  40. Wiles NJ, Mulligan J, Peters TJ, Cowen PJ, Mason V, Nutt D, Sharp D, Tallon D, Thomas L, O'Donovan MC, Lewis G (2012) Severity of depression and response to antidepressants: GENPOD randomised controlled trial. Br J Psychiatry 200:130–136 · DOI

Cited by

See all 69

Metadata

Authors
Crawford, A. A., Lewis, S., Nutt, D., Peters, T. J., Cowen, P., O’Donovan, M. C., Wiles, N., & Lewis, G.
Venue
Psychopharmacology
Published
2014-02-13
Volume
231
Issue
15
Pages
2921-2931
ISSN
  • 0033-3158 (ISSN-L)
  • 1432-2072
OpenAlex
W1968895338
Cited by
69
References
10
FWCI
3.46
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Adverse effects from antidepressant treatment: randomised controlled trial of 601 depressed individuals. https://app.cochat.ai/papers/10.1007/s00213-014-3467-8
The paper
Crawford, A. A., Lewis, S., Nutt, D., Peters, T. J., Cowen, P., O’Donovan, M. C., Wiles, N., & Lewis, G. (2014). Adverse effects from antidepressant treatment: randomised controlled trial of 601 depressed individuals. Psychopharmacology. https://doi.org/10.1007/s00213-014-3467-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.